Drug Makers Stock Performance Review -- Apricus Biosciences, DURECT, Sucampo Pharma, and Depomed

Tuesday, September 26, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, September 26, 2017 /PRNewswire/ --

If you want a Stock Review on APRI, DRRX, SCMP, or DEPO then come over

to http://dailystocktracker.com/register/ and sign up for your free customized report. Research coverage has been initiated by DailyStockTracker.com on Apricus Biosciences Inc. (NASDAQ: APRI), DURECT Corp. (NASDAQ: DRRX), Sucampo Pharmaceuticals
Inc. (NASDAQ: SCMP), and Depomed Inc. (NASDAQ: DEPO). Companies in the Drug Manufacturers industry manufacture and process pharmaceutical products.  The profitability of individual companies depends on their ability to discover and market new drugs. These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at: http://dailystocktracker.com/register/

Apricus Biosciences 

San Diego, California headquartered Apricus Biosciences Inc.'s stock finished Monday's session 2.98% higher at $1.73 with a total trading volume of 189,407 shares. Over the last month and the previous three months, the Company's shares have advanced 7.45% and 61.68%, respectively. Additionally, the stock has gained 33.08% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 19.93% and 5.34%, respectively. Moreover, shares of Apricus Biosciences, which focuses on the development and commercialization of product candidates in the areas of urology and rheumatology, have a Relative Strength Index (RSI) of 60.87.

On August 31st, 2017, Apricus Biosciences announced that the US FDA has acknowledged the receipt of its recently resubmitted New Drug Application (NDA) for Vitaros™ (alprostadil, DDAIP.HCl) and considers it a complete, class 2 response to the Company's 2008 action letter. The Prescription Drug User Fee Act goal date for completion of the FDA's review of the Vitaros NDA is set for February 17th, 2018, which is the standard six-month review period for NDA resubmissions. Your complete research report on APRI can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=APRI

DURECT 

Shares in Cupertino, California headquartered DURECT Corp. declined 2.89%, ending yesterday's session at $1.68 with a total trading volume of 239,361 shares. The stock has gained 5.00% in the past month, 12.00% in the previous three months, and 25.37% on an YTD basis. The Company's shares are trading 0.11% above their 50-day moving average and 30.90% above their 200-day moving average. Moreover, shares of DURECT, which researches and develops medicines based on its epigenetic regulator and drug delivery programs, have an RSI of 53.10.  

On September 20th, 2017, DURECT announced that Dr. Myriam Theeuwes has joined the Company as Senior Vice President, Clinical Development. Dr. Theeuwes joins the Company from Johnson & Johnson where she spent 18 years, most recently as Compound Development Team Leader for Janssen Pharmaceutical's global public health initiatives. A free report on DRRX is just a click away at: http://dailystocktracker.com/registration/?symbol=DRRX

Sucampo Pharmaceuticals 

On Monday, Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc.'s stock rose 0.42%, to close the day at $11.85. A total volume of 412,105 shares was traded. The Company's shares have advanced 5.80% in the last one month and 10.23% in the previous three months. The stock is trading 5.40% an 5.03% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Sucampo Pharma, which focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the US, Japan, Switzerland, and internationally, have an RSI of 51.20.  

On September 20th, 2017, Sucampo Pharma announced the appointment of Alex Driggs to General Counsel and Corporate Secretary. Mr. Driggs joined the Company in May 2015 as Associate General Counsel, was appointed its Deputy General Counsel in September 2015, and has most recently served as Acting General Counsel and Corporate Secretary since June 2017. Sign up for your complimentary research report on SCMP at: http://dailystocktracker.com/registration/?symbol=SCMP

Depomed 

Shares in Newark, California headquartered Depomed Inc. ended the day 1.19% higher at $5.97. A total volume of 1.37 million shares was traded. The stock is trading below its 50-day moving average by 21.35%. Furthermore, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have an RSI of 30.89.  

On August 28th, 2017, Depomed announced that it has been selected to join the Collaborative for Effective Prescription Opioid Policies, a diverse group of over 70 stakeholders creating and advancing policies and educational initiatives aimed at reducing opioid abuse and promoting treatment options for those living with pain or confronting addiction. Register for free on DailyStockTracker.com and download the latest research report on DEPO at: http://dailystocktracker.com/registration/?symbol=DEPO

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook